Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 5/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15392785 | 0.89 | DPP4 (0.47) | MALT1CNR1CRHR1DPP4DPP8 | |
| SCHEMBL4911607 | 0.88 | HSD11B1 (0.43) | MALT1HSD11B1CRHR1DPP4DPP8 | |
| SCHEMBL4934709 | 0.86 | DPP4 (0.48) | HSD11B1DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL4918479 | 0.85 | DPP4 (0.47) | HSD11B1DPP4DPP8 | |
| SCHEMBL5187409 | 0.80 | DPP4 (0.44) | CRHR1DPP4DPP8 | |
| SCHEMBL15392959 | 0.79 | MALT1 (0.44) | MALT1CNR1DPP4 | |
| Hydrochloric Acid SCHEMBL4913608 | 0.79 | DPP4 (0.43) | CRHR1DPP4DPP8 | |
| SCHEMBL5202471 | 0.78 | DPP4 (0.55) | CNR1CRHR1DPP4DPP8 | |
| SCHEMBL3889534 | 0.77 | CNR1 (0.50) | CNR1DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL4912438 | 0.77 | DPP4 (0.54) | CNR1CRHR1DPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080021070-A1 | PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | US | disclosed |
| EP-1805143-A1 | PYRIDINE DERIVATIVES AND THE PREPARATION AND THE THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006042955-A1 | PYRIDINE DERIVATIVES AND THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021070-A1 | PYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | CNR1, CNR2, GPR18 | MALT1 1639/4885CNR1 1/4885HSD11B1 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.